SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

The U.S. Department of Health and Human Services has awarded Moderna (MRNA) $590M to “advance the late-stage development of its mRNA bird flu ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about a range of issues including the impact of Trump’s ...

Biotech has lagged even more. The S&P Biotechnology Select Industry Index has returned about 3 per cent annually over 10 ...

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...

Moderna secured a $590 million package from the U.S. Health and Human Services Department to accelerate the development of its bird influenza vaccine. The financial package will fund the expansion of ...